Anti-HER2/neu therapy in DCIS

Amelia Tower, Ruta D. Rao, Kalliopi P. Siziopikou, Melody A. Cobleigh, Thomas B. Julian*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter


Ductal carcinoma in situ (DCIS) is a heterogeneous form of preinvasive breast cancer, with subtypes that are comparable to those of invasive disease. Targeted molecular therapies have improved outcomes for patients with invasive breast cancer, and we have parallel opportunities for advances in personalized treatment of DCIS. Early work has demonstrated synergy between human epidermal growth factor receptor (HER)2-targeted therapy and radiotherapy. Anti-HER2 therapy may also induce an immune response. This chapter addresses the history of research regarding HER2 expression in DCIS as well as ongoing clinical trials that address whether HER2-targeted therapy will improve patient outcomes in DCIS.

Original languageEnglish (US)
Title of host publicationDuctal Carcinoma in Situ and Microinvasive/Borderline Breast Cancer
PublisherSpringer New York
Number of pages10
ISBN (Electronic)9781493920358
ISBN (Print)9781493920341
StatePublished - Jan 1 2015


  • Ductal carcinoma in situ
  • HER2/neu
  • Radiotherapy
  • Trastuzumab

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Anti-HER2/neu therapy in DCIS'. Together they form a unique fingerprint.

Cite this